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Janus kinase 2 (JAK2) is an intracellular tyrosine 
kinase that associates with the cytoplasmic do­
mains of multiple cytokine receptors. Ligand 
binding by the receptor results in conformational 
changes that activate JAK2, resulting in phospho­
rylation of target proteins, including STATs and 
JAK2 itself (Ihle and Gilliland, 2007). More than 
50% of myeloproliferative neoplasms (MPNs) 
harbor  the  activating  JAK2 V617F  mutation 
(Levine et al., 2005, 2007). In addition, a subset of 
B cell acute lymphoblastic leukemia (B­ALL) with 
rearrangements of cytokine receptor–like factor 2 
(CRLF2) have activating JAK2 mutations that 
primarily involve R683 (Mullighan et al., 2009a; 
Russell et al., 2009; Hertzberg et al., 2010;   
Yoda et al., 2010). Additional cases of CRLF2­ 
rearranged B­ALL lack JAK2 mutations but 
harbor a CRLF2 F232C or IL7R mutation (Yoda   
et al., 2010; Shochat et al., 2011) that promotes 
constitutive receptor dimerization and signaling 
through wild­type JAK2, which is analogous to 
the MPL W515L mutation observed in a subset 
of MPNs (Pikman et al., 2006).
CORRESPONDENCE  
David M. Weinstock:  
dweinstock@partners.org  
OR  
Thomas Radimerski:  
thomas.radimerski@novartis.com
Abbreviations used: B­ALL,  
B cell acute lymphoblastic leuke­
mia; CRLF2, cytokine receptor–
like factor 2; EpoR, 
erythropoietin receptor; GSEA, 
gene set enrichment analysis;  
HSF, heat shock factor; HSP, heat   
shock protein; JAK, Janus kinase; 
JAKinh­1, JAK inhibitor­1; JH1, 
JAK homology domain 1; MPN,   
myeloproliferative neoplasm; 
NSG, NOD.Cg­Prkdcscid  
Il2rgtm1Wjl/SzJ; RFU, relative 
fluorescence unit; VF,  
Ba/F3­EpoR/Jak2 V617F.
Genetic resistance to JAK2 enzymatic 
inhibitors is overcome by HSP90 inhibition
Oliver Weigert,1 Andrew A. Lane,1 Liat Bird,1 Nadja Kopp,1  
Bjoern Chapuy,1 Diederik van Bodegom,1 Angela V. Toms,2,7  
Sachie Marubayashi,5 Amanda L. Christie,4 Michael McKeown,1  
Ronald M. Paranal,1 James E. Bradner,1 Akinori Yoda,1 Christoph Gaul,6 
Eric Vangrevelinghe,6 Vincent Romanet,6 Masato Murakami,6 Ralph Tiedt,6 
Nicolas Ebel,6 Emeline Evrot,6 Alain De Pover,6 Catherine H. Régnier,6 
Dirk Erdmann,6 Francesco Hofmann,6 Michael J. Eck,2,7 Stephen E. Sallan,4 
Ross L. Levine,5 Andrew L. Kung,3,4,8 Fabienne Baffert,6  
Thomas Radimerski,6 and David M. Weinstock1,8
Departments of 1Medical Oncology, 2Cancer Biology, 3Pediatric Oncology, and the 4Lurie Family Imaging Center, Dana-Farber 
Cancer Institute, Boston, MA 02115
5Human Oncology Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York,  
New York 10065
6Novartis Institute for Biomedical Research, CH-4057 Basel, Switzerland
7Department of Biological Chemistry and Molecular Pharmacology and 8Department of Biological and Biomedical Sciences, 
Harvard Medical School, Boston, MA 02115
Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment 
of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL)  
with rearrangements of the cytokine receptor subunit cytokine receptor–like factor 2 
(CRLF2), and other tumors with constitutive JAK2 signaling. In this study, we identify 
G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance 
across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in 
MPNs) or JAK2 R683G (observed in B-ALL). G935R, Y931C, and E864K do not reduce the 
sensitivity of JAK2-dependent cells to inhibitors of heat shock protein 90 (HSP90), which 
promote the degradation of both wild-type and mutant JAK2. HSP90 inhibitors were  
100–1,000-fold more potent against CRLF2-rearranged B-ALL cells, which correlated with 
JAK2 degradation and more extensive blockade of JAK2/STAT5, MAP kinase, and AKT 
signaling. In addition, the HSP90 inhibitor AUY922 prolonged survival of mice xenografted 
with primary human CRLF2-rearranged B-ALL further than an enzymatic JAK2 inhibitor. 
Thus, HSP90 is a promising therapeutic target in JAK2-driven cancers, including those with 
genetic resistance to JAK enzymatic inhibitors.
© 2012 Weigert et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e260 HSP90 inhibition targets resistant JAK2 | Weigert et al.
at the same concentrations in JAK3 A572V mutant CMK and 
BCR-ABL1 rearranged K­562 cells (Fig. 1 C). BVB808 rap­
idly and potently blocked JAK2­dependent phosphorylation   
of STAT5 (pSTAT5) and induced PARP cleavage in JAK2 
V617F­dependent MB­02 and SET­2 cells (Fig. 1, D–G). 
Inhibition  of  pSTAT5  required  an  10­fold  higher  dose   
of BVB808 in CMK cells compared with MB­02 and SET­2 
cells, consistent with the preferential activity against JAK2   
(Fig. 1, D and E).
To determine the in vivo activity of BVB808, we used a 
bone marrow transplant model of Jak2 V617F­driven MPN. 
Bone marrow from BALB/c mice was transduced with Jak2 
V617F and transplanted into congenic recipients. Upon de­
velopment of polycythemia, mice were randomized to treat­
ment with 50 mg/kg of either vehicle or BVB808 twice daily. 
After 3 wk of treatment, mice were sacrificed and assessed 
for pharmacodynamic and clinical endpoints. Compared with 
controls, BVB808­treated mice had reduced reticulocyte 
(mean ± SEM; 0.7 ± 0.1 versus 0.4 ± 0.10 × 1012/liter; n = 3–6) 
and WBC counts (19.9 ± 3.0 versus 11.4 ± 3.2 × 109/liter;   
n = 3–6). BVB808 reduced bone marrow hypercellularity 
(Fig. 1 H), normalized spleen weight (Fig. 1 I), and suppressed 
pSTAT5 in both spleen and bone marrow (Fig. 1 J).
Point mutations in the JAK2 kinase domain confer 
resistance to JAK inhibitors
Mutations in tyrosine kinases are a common cause of genetic 
resistance to enzymatic inhibitors (Engelman and Settleman, 
2008). To identify resistance mutations in JAK2, we modi­
fied an approach that was previously applied to identify 
BCR/ABL1 mutations that confer resistance to imatinib 
(Azam et al., 2003). Expression of CRLF2 with a JAK2 
R683G renders murine Ba/F3 cells capable of growth in the 
absence of IL­3 (Mullighan et al., 2009a; Russell et al., 2009; 
Hertzberg et al., 2010; Yoda et al., 2010). We randomly 
mutagenized human JAK2 R683G cDNA and transduced 
the mutagenized cDNA library into Ba/F3 cells expressing 
CRLF2 (Ba/F3­CRLF2; Fig. 2 A). The transduced popula­
tion was selected in 1 µM BVB808 in the absence of IL­3 
(Fig. 2 A). Within 2–3 wk, multiple BVB808­resistant clones 
expanded from single cells. We sequenced the mutagenized 
JAK2  R683G  cDNA  from  genomic  DNA  of  individual 
BVB808­resistant clones and identified multiple clones with 
E864K, Y931C, or G935R mutations.
Even in the absence of a transforming oncogene, trans­
duction of Ba/F3 cells can occasionally result in individual 
clones that have escaped IL­3 independence through non­
JAK2–mediated signaling. If this occurred, the surviving IL­3–
independent cells would be resistant to JAK2 inhibitors but 
not dependent on JAK2. Thus, we took three approaches to 
confirm that the cells expressing E864K, Y931C, or G935R   
in cis with a JAK2 gain­of­function allele are dependent on 
JAK2 function and resistant to enzymatic inhibitors. First, 
we recloned the mutations into human JAK2 R683G cDNA 
by site­specific mutagenesis and confirmed their ability to confer 
BVB808 resistance when expressed in combination with 
Constitutive signaling through wild­type JAK2 contrib­
utes to the proliferation of many other cancers, including 
myeloid malignancies (Najfeld et al., 2007; Wardrop and 
Steensma, 2009), B cell lymphomas (Green et al., 2010; 
Rui et al., 2010), and hormone receptor–/ERBB2­negative 
breast cancers (Marotta et al., 2011). Thus, JAK2 is emerging 
as an attractive target with broad therapeutic potential.
Multiple  ATP­mimetic  inhibitors  of  JAK2  are  under 
development (Verstovsek, 2009). In patients with MPN, 
JAK2 inhibitors can reduce JAK2 allele burden, spleen size, 
and constitutional symptoms (Pardanani et al., 2011; Verstovsek 
et al., 2011), but have not resulted in molecular remissions 
like those observed in patients treated with tyrosine kinase 
inhibitors for tumors with ABL1, B-RAF, or C-KIT altera­
tions (Druker et al., 2001; Joensuu et al., 2001; Flaherty   
et al., 2010). This observation could result from a lack of 
addiction to JAK2 signaling in MPNs, which is supported 
by the variable allele frequency of JAK2 V617F among   
malignant cells in most patients. In contrast with MPNs, 
CRLF2-rearranged B­ALL with JAK2 mutations appear to 
harbor the JAK2 mutation in essentially all leukemic cells 
(Mullighan et al., 2009b; Yoda et al., 2010), which may in­
dicate more extensive addiction and therefore greater thera­
peutic benefit from inhibiting JAK2.
Among cancers dependent on tyrosine kinases, treatment 
with  ATP­mimetic  inhibitors  has  invariably  resulted  in  the   
development of inhibitor resistance mutations (Engelman 
and  Settleman,  2008).  Using  the  novel  JAK2  inhibitor 
NVP_BVB808 (BVB808), we recovered E864K, Y931C, and 
G935R mutations within the kinase domain of JAK2 that 
confer  resistance  to  multiple  JAK2  enzymatic  inhibitors.  In   
addition, we show that treatment with inhibitors of heat 
shock protein 90 (HSP90) can overcome all three resistance 
mutations and potently kill cells dependent on JAK2. Finally, 
we demonstrate that the HSP90 inhibitor NVP_AUY922 
(AUY922) more potently suppresses JAK–STAT, MAP kinase, 
and AKT signaling than BVB808, which translates into pro­
longed survival in mice xenografted with human B­ALL.
RESULTS
BVB808 is a selective JAK2 inhibitor with activity in vivo
Inhibitors of JAK2 enzymatic activity offer potential thera­
peutic benefit for patients with malignant and nonmalignant 
diseases that have constitutive JAK2 signaling (Kiss et al., 
2010).  We assayed the activity of BVB808, a novel JAK2   
inhibitor  of  the  N­aryl­pyrrolopyrimidine  scaffold  class 
(Fig. 1 A). BVB808 has 10­fold selectivity in vitro for JAK2 
compared with JAK1, JAK3, or TYK2 (Fig. 1 B) and exhib­
ited >100­fold selectivity for JAK2 in a kinase assay panel con­
sisting of 66 Ser/Thr/Tyr/lipid kinases, with the exception   
of cABL1 (40×), cABL1 T315I (75×), ROCK2 (70×), and 
PI3K (70×; unpublished data). BVB808 potently killed 
JAK2­dependent cell lines and MPL W515L­driven Ba/F3 
cells, as well as FLT­3 ITD mutant MV4­11 cells, with half­
maximal growth inhibitory (GI50) concentrations ≤60 nM 
(Fig. 1 C). In contrast, modest growth inhibition was observed JEM Vol. 209, No. 2 
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Figure 1.  JAK2 signaling as a therapeutic target. (A) Chemical structure of BVB808. (B) Kinase assays were performed with recombinant kinase 
(JH1) domains of the respective JAKs to determine the relative JAK-family selectivity of BVB808. (C) BVB808 activity against JAK2-dependent and 
JAK2-independent cell lines. GI50 values represent means of at least two independent experiments (n = 2–4). (D) JAK2 V617F mutant MB-02 cells were 
treated with increasing concentrations of BVB808 for 30 min. Inhibition of constitutive pSTAT5 was analyzed by Western blotting using a Tyr694 
phospho-specific antibody. Total STAT5 is included as a loading control. (E) JAK2 V617F mutant SET-2 and JAK3 A572V mutant CMK cells were treated 
with increasing concentrations of BVB808 for 1 h, and then extracted for immunoblotting. (F and G) MB-02 and SET-2 cells were treated with 1 µM 
BVB808 for up to 24 h. Cell extracts were prepared at different time points as indicated and probed for pSTAT5. Activation of cell death was assessed 
by detection of cleaved PARP (arrowhead). -Tubulin was used as a loading control. (H) Efficacy of BVB808 was evaluated in a mouse bone marrow 
transplant model of Jak2 V617F–driven MPN after 3 wk of dosing. Bar, 100 µm. (I) In a separate experiment, CT imaging of mice before treatment and 
after 3 and 50 d of vehicle or BVB808. After imaging on day 50, the mice were sacrificed and the spleens were dissected and weighed. Spleen weight 
is shown on the right. Bar, 1 cm. (J) Immunohistochemistry for pStat5 in spleen and bone marrow sections from samples collected 2 h after the last 
dose of vehicle or BVB808. Bar, 50 µm.262 HSP90 inhibition targets resistant JAK2 | Weigert et al.
Figure 2.  JAK2 alleles that confer resistance to enzymatic inhibitors. (A) In vitro mutagenesis screen of JAK2 R683G in Ba/F3-CRLF2 cells to iden-
tify mutations that confer resistance to BVB808. (B) Sensitivity to BVB808 was reduced in Ba/F3-CRFL2/JAK2 R683G cells harboring Y931C (GI50, 303 nM), 
G935R (462 nM), or E864K (427 nM) compared with no resistance mutation (96.4 nM; P < 0.05 for all 3 mutants). Proliferation was measured based on 
relative fluorescence units (RFU). Error bars represent SD. (C) Ba/F3 cells expressing ATIC-ALK (ALK+), EpoR/Jak2 V617F alone (none), or EpoR/Jak2 V617F 
with one of the three kinase domain mutations were transfected with either of two siRNA (#4 and #2) targeting mouse Jak2. The cells were grown in the 
absence of IL-3, and proliferation was measured after 24 and 48 h and normalized to cells from the same background transfected with nontargeting (nt) 
control siRNA. Representative immunoblot of VF/Y931C cells 24 h after transfection is shown. (D) Alignment of homologous regions in JAK2 and ABL1. JEM Vol. 209, No. 2 
Article
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in the N­lobe (Fig. 2 E) and may modify the structure and 
flexibility of the preceding P­loop, thus destabilizing the 
conformation required for inhibitor binding.
Mutations in the JAK2 kinase domain confer resistance 
across a panel of JAK inhibitors
To determine whether the mutations confer resistance in the 
context of Jak2 V617F, we expressed Jak2 V617F alleles har­
boring Y931C, G935R, or E864K in Ba/F3 cells express­
ing EpoR. For these experiments, we used a panel of JAK   
enzymatic inhibitors (Fig. 2 F) that included tool compounds 
(JAK inhibitor­1 [JAKinh­1] and NVP­BSK805 [BSK805; 
Baffert et al., 2010]) and agents in late­stage clinical trials 
(TG101348 [Pardanani et al., 2011; Wernig et al., 2008], 
tofacitinib [formerly tasocitinib; Manshouri et al., 2008], and 
ruxolitinib [formerly INCB18424; Pardanani, 2008]).
Y931C conferred a 2 to >10­fold resistance to all the JAK 
inhibitors (Fig. 2, G and H; and Table S1). G935R conferred 
resistance to all JAK inhibitors except for tofacitinib. E864K 
only conferred resistance to BVB808 and BSK805 (Fig. 2,   
G and H; and Table S1).
HSP90 inhibitors target JAK2 and overcome resistance  
to enzymatic kinase inhibitors
JAK2 is a known client of HSP90 (Marubayashi et al., 2010). 
Inhibition of HSP90 promotes the degradation of both wild­
type and mutant JAK2 (Bareng et al., 2007; Wang et al., 2009; 
Proia et al., 2011), and can improve survival in murine models 
of Jak2­dependent MPNs (Marubayashi et al., 2010). We 
hypothesized that resistance mutations within the JAK2 kinase 
domain would not affect JAK2 degradation induced by HSP90 
inhibitors. We assayed the cytotoxicity of the resorcinylic 
isoxazole amide AUY922 (Fig. 2 F; Eccles et al., 2008) and the 
benzoquinone ansamycin 17­AAG in Ba/F3­EpoR cells that 
express  Jak2  V617F  (and  Ba/F3­CRLF2  cells  that  express 
JAK2 R683G) with or without E864K, Y931C, or G935R. 
E864K, Y931C, and G935R did not confer resistance to either 
compound (Fig. 2, G and H; and Table S1). In fact, AUY922 was 
more potent against cells harboring Y931C (GI50, 4.92 nM), 
G935R (GI50, 6.44 nM), or E864K (GI50, 6.38 nM) com­
pared with cells with no second site mutation (GI50, 10.00 nM; 
P < 0.05; Fig. 2, G and H; and Table S1).
JAK2 G935R blocks binding of some but not all inhibitors
We previously solved the co­crystal structure of the JAK2 
JH1 domain in complex with BSK805 (Baffert et al., 2010). 
Using this structure, modeling of G935R indicated that an 
CRLF2 (Fig. 2 B). Second, we cloned all three mutations 
independently in cis with mouse Jak2 V617F and expressed 
them with the erythropoietin receptor (EpoR) in Ba/F3 cells. 
Concurrent expression of Jak2 V617F with EpoR confers IL­3 
independence in Ba/F3 cells (Levine et al., 2005). As expected, 
cells  expressing  EpoR  with  Jak2  V617F  alleles  harboring 
E864K, Y931C, or G935R also conferred IL­3 independence 
and resulted in multiagent resistance to JAK2 enzymatic inhib­
itors, similar to that noted for Ba/F3­CRLF2 cells harboring 
the resistance alleles in cis with JAK2 R683G (Table S1). Thus, 
all three alleles maintain their ability to confer resistance 
whether present in human or mouse JAK2, whether expressed 
in cis with the R683G or V617F mutation, and whether sig­
naling through CRLF2 or EpoR. Finally, all three lines, but 
not Ba/F3 cells dependent on ALK, were killed by Jak2 siRNA 
knockdown, indicating dependence on Jak2 (Fig. 2 C).
Three previous works identified mutations that conferred 
resistance to one or more JAK inhibitors by screening Ba/F3 
cells with EpoR and mutagenized JAK2 V617F or TEL­JAK2 
(Table S2). Of note, E864K, Y931C, and G935R are the only 
mutations identified by multiple groups (including ours) through 
unbiased screening, strongly suggesting that they are bona fide 
resistance mutations. In a separate screen of mutagenized 
TEL­JAK2 expressed in Ba/F3 cells, we recovered the Y931S 
mutation after selection in BVB808 (Table S2), providing fur­
ther evidence that this residue is critical for enzymatic JAK in­
hibitor activity. In addition, alignment of homologous regions 
of the JAK2 kinase domain (JAK homology domain 1 [JH1]) 
with ABL1 demonstrated that E864K, Y931C, and G935R are 
located in regions homologous to imatinib resistance hotspots in 
ABL1 (Fig. 2 D; Azam et al., 2003; Soverini et al., 2011).
Resistance mutations are located near the ATP-binding 
region of the JAK2 kinase domain
We performed structural modeling to evaluate the possible 
consequences of the three JAK2 resistance mutations (Fig. 2 E). 
Codons Y931 and G935 are located in the hinge region of 
the kinase domain (Fig. 2 E). G935R introduces a large and 
positively  charged  side  chain  that  could  sterically  hinder 
drug binding (Fig. 2 E). Y931 is located in the adenine­
binding region of the hinge and can interact directly with 
ATP­competitive inhibitors (Lucet et al., 2006). Y931C re­
places a tyrosine, which is predicted to reduce inhibitor 
binding affinity. Introduction of a cysteine at this site also 
creates the potential for a targeted covalent inhibitor specific 
for this mutation, as previously demonstrated (Zhou et al., 
2010). E864K is located in the middle of 3 after the P­loop 
Blue arrows indicate mutated codons in BCR/ABL1 reported to confer imatinib resistance in patients (Soverini et al., 2011). Black arrows indicate codons 
identified by in vitro mutagenesis of BCR/ABL1 (Azam et al., 2003) and JAK2 E864K, Y931C, and G935R mutations (below). (E) Structure of the kinase  
domain of JAK2 indicating E864, Y931, and G935 (right), with modeling of wild type, Y931C, and G935R (left, top to bottom). (F) Chemical structures of 
JAK inhibitors and the HSP90 inhibitor AUY922. (G) E864K, Y931C, and G935R were introduced into Jak2 V617F and expressed in Ba/F3-EpoR cells. Prolif-
eration was assayed 48 h after exposure to indicated drug or vehicle in triplicate on two occasions based on RFU. *, P < 0.05 compared with no resistance 
mutation for that drug (GI50 in nanomolar in parentheses). (H) Dose response curves based on RFU after 48 h of treatment with indicated drugs. Each 
data point was obtained in quadruplicate, and the experiment was independently repeated three times. Error bars indicate SD.
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BVB808 treatment partially reduced activation state–specific 
phosphorylation of Stat5 in Ba/F3­EpoR/Jak2 V617F (VF) cells, 
but not in VF/G935R (Fig. 3 B) or VF/G935H cells (Fig. S1 B).   
BVB808 resulted in a paradoxical increase in Jak2 phospho­
rylation at Y1007/Y1008 within the Jak2 activation loop in VF 
but not in VF/G935R cells (Fig. 3 B), a phenomenon previously 
reported upon treatment of JAK2­dependent cells with other 
JAK2 enzymatic inhibitors (Grandage et al., 2006; Haan et al., 
2009; Hart et al., 2011). Treatment of both lines with AUY922 
at levels achievable in vivo (Eccles et al., 2008) reduced pJak2, 
pStat5, and total Jak2 (Fig. 3 B). Thus, 
HSP90 inhibitors maintain activity in 
Jak2­dependent cells with genetic resis­
tance to enzymatic inhibitors.
AUY922 is effective in vivo against 
cells dependent on resistant JAK2
To determine whether the resistance mu­
tations compromise JAK2­dependent 
proliferation, we performed a competi­
tive growth assay between VF cells 
and cells harboring Jak2 V617F with 
Y931C,  G935R,  or  E864K  in  1:1 
mixtures (Fig. 3 C). Over a 20­d growth 
arginine side chain would occlude the hydrophobic channel 
of the ATP­binding pocket. As a consequence, this muta­
tion would decrease the binding affinity of compounds   
occupying  the  hydrophobic  channel  like  JAKinh­1  or 
BSK805, but not affect the potency of tofacitinib, which 
does not bind in this region. Mutation of G935 to arginine, 
histidine,  or  glutamine  reduced  the  inhibitory  effects  of 
JAKinh­1, but not tofacitinib, on JAK2 kinase domain activ­
ity (Fig. 3 A and Fig. S1 A). None of the codon 935 mutations 
had significant effects on Km or Vmax in vitro (Fig. S1 A).
Figure 3.  Functional characterization  
of resistance mutations in JAK2 V617F.  
(A) IC50 values of tofacitinib or JAKinh-1  
determined using purified wild-type, G935Q, 
G935H, or G935R JAK2 kinase domains.  
(B) Ba/F3-EpoR/HA-Jak2 V617F or Ba/F3-EpoR/
HA-Jak2 V617F/G935R cells were treated with 
the indicated drugs for 16 h, and lysates were 
immunoblotted with antibodies against hemag-
glutinin (HA) or the indicated proteins.  
(C) Ba/F3-EpoR cells expressing Jak2 V617F-
Thy1.1 and Ba/F3-EpoR cells expressing Jak2 
V617F/Y931C-GFP (top)/G935R-GFP (middle)/
or E864K-GFP (bottom) were mixed 1:1. The 
relative fraction of each cell population  
was quantified by flow cytometry in the  
presence or absence of drug, as indicated.  
(D) Mice injected with 1:1 mixes of luciferized 
Ba/F3-EpoR-JAK2 V617F-Thy1.1 and luciferized 
Ba/F3-EpoR-Jak2 V617/Y931C-GFP cells were 
treated with AUY922 (n = 8) or vehicle (n = 9) 
and luciferase was measured at indicated time 
points. Error bars indicate standard error of  
the mean. *, P < 0.05 compared with vehicle.  
(E) Representative luciferase imaging of 
AUY922- and vehicle-treated mice on day 8 of 
treatment. (F) Survival of mice treated with 
vehicle or AUY922. (G) Peripheral blood was 
analyzed from mice treated with vehicle (V) or 
AUY922 (A) by flow cytometry for percentage 
of mononuclear cells expressing GFP (Jak2 
V617F/Y931C) or Thy1.1 (Jak2 V617F). 4 mice 
were analyzed at each time point except for 
vehicle day 11 (n = 2). Error bars indicate SEM.JEM Vol. 209, No. 2 
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vehicle or AUY922 thrice weekly i.v.. The dose of AUY922 
was selected based on previous activity in preclinical breast can­
cer models (Jensen et al., 2008). In addition, we demonstrated   
that this dose of AUY922 reduces spleen size and hematocrit   
in the Jak2 V617F bone marrow transplant model of MPN.
AUY922 reduced bioluminescence compared with vehicle 
(Fig. 3, D and E), which was associated with an improvement 
in overall survival for AUY922­treated mice (Fig. 3 F; P = 
0.0147). To clarify whether the activity of AUY922 was   
affected by the Y931C mutation, we performed flow cytom­
etry on peripheral blood after 4, 7, and 11 d of treatment. 
AUY922 treatment did not increase the relative ratio of cells 
expressing JAK2 V617F/Y931C compared with cells expressing 
JAK2 V617F alone, consistent with similar activity independent 
of the resistance mutation (Fig. 3 G).
HSP90 inhibitors have potent activity  
in CRLF2-rearranged B-ALL cells
Outcomes among patients with CRLF2-rearranged B­ALL 
are poor, with <20% relapse­free survival among adults (Yoda 
et al., 2010) and 40% among children 
(Harvey et al., 2010). To explore the 
utility of HSP90 inhibition in CRLF2­ 
rearranged  B­ALL,  we  exposed  the 
MHH­CALL4  and  MUTZ­5  cell 
lines, which both have CRLF2/IGH 
rearrangements to AUY922. MHH­
CALL4 cells also harbor a JAK2 I682F 
mutation,  whereas  MUTZ­5  cells 
have a JAK2 R683G mutation. Both 
MUTZ­5 and MHH­CALL4 were 
highly  sensitive  to  AUY922  (GI50, 
25–26 nM), with 50 to >1,000­fold 
period, cells harboring Jak2 V617F/Y931C had no com­
petitive growth disadvantage, whereas cells harboring Jak2 
V617F/G935R or JAK2 V617F/E864K were outcompeted   
by VF cells (Fig. 3 C).
Treatment of the 1:1 mixtures with BVB808 led to a rapid 
predominance of cells harboring the resistance mutation over 
VF cells (Fig. 3 C). Treatment of all three mixtures with AUY922 
resulted in <2% viability within 48 h. Strikingly, cells harboring 
Jak2 V617F alone predominated among surviving cells, consis­
tent with the increased potency of AUY922 against cells harbor­
ing the resistance mutations (Fig. 2, G and H; and Table S1).
To determine whether AUY922 is effective in vivo against 
cells harboring Jak2 enzymatic inhibitor resistance, we trans­
planted nude mice with a 1:1 mix of luciferized Ba/F3 cells   
expressing (a) EpoR/Jak2 V617F/Y931C with GFP, and (b) 
EpoR/Jak2 V617F alone with Thy1.1. We elected to transplant 
a 1:1 mix to allow for monitoring of the effects of AUY922   
on both Jak2 V617F– and Jak2 V617F/Y931C–dependent 
cells. Once luciferase activity was measurable in the mice 
(day 4 after injection), we treated them with 50 mg/kg of either 
Figure 4.  JAK2 and HSP90 inhibition in 
CRLF2-rearranged B-ALL cell lines.  
(A) MHH-CALL4 and MUTZ-5 cells were  
exposed to JAK2 enzymatic inhibitors and the 
HSP90 inhibitor AUY922 at indicated concen-
trations for 96 h, and proliferation was quanti-
fied based on RFU. Error bars represent SD. 
Shown results are representative of two inde-
pendent experiments performed in quadrupli-
cate. (B) GI50 concentrations for JAK2 and 
HSP90 inhibitors after 2 d (Ba/F3 cell lines) or  
3 d (MHH-CALL4 and MUTZ-5 cell lines) of 
exposure. K562 cells harbor BCR/ABL1 and not 
CRLF2 rearrangements. (C) Immunoblotting in 
MHH-CALL4 and MUTZ-5 cells exposed to  
1 µM JAKinh-1, 50 nM AUY922, combination, 
or vehicle for 16 h. (D) MHH-CALL4 cells were 
transfected with siRNA against the indicated 
JAK family member or with scrambled control, 
and lysates were collected for immunoblotting 
after 72 h. (E) Immunoblotting of Ba/F3-CRLF2/
JAK2 R683G cells for the indicated total or 
phosphorylated proteins after treatment with 
the indicated doses of HSP990 or PU-H71.266 HSP90 inhibition targets resistant JAK2 | Weigert et al.
with  AUY922  alone  (Fig.  4  C).  In  addition,  pairwise 
dose–response studies with isobologram analysis failed to 
identify synergistic effects from combination treatment with 
AUY922+BVB808  in  MHH­CALL4  or  MUTZ­5  cells   
(unpublished data).
HSP90 inhibition elicits a transcriptional signature enriched 
for JAK2 and HSF1 signaling
To compare the downstream programs resulting from JAK2 
and HSP90 inhibition, we performed transcriptional profil­
ing on MUTZ­5 and MHH­CALL4 cells treated with vehi­
cle (DMSO), JAKinh­1, AUY922, or JAKinh­1+AUY922 
(combo). Unsupervised hierarchical clustering distinguished 
samples treated with AUY922 (or combination) from those 
treated with JAKinh­1 or vehicle (Fig. 5 A). We generated   
a  heat  map  of  the  top/bottom  differentially  expressed 
genes for each condition (false discovery rate (FDR) <0.25 
and fold change (FC)>2.5; Table S3), which indicated that 
AUY922  treatment  modulated  the  same  genes  targeted   
by JAKinh­1 (Fig. 5 B), but to a larger extent. GSEA also 
demonstrated that STAT5A signatures were enriched upon 
treatment with JAKinh­1, AUY922, or JAKinh­1+AUY922 
(Fig. 5 C). To formally demonstrate that AUY922 targets 
the same genes as JAKinh­1, we defined a “JAK inhibitor 
signature” from the top/bottom 250 most differentially ex­
pressed genes after treatment with JAKinh­1. Using gene 
set enrichment analysis (GSEA), the JAK inhibitor signature   
was highly enriched upon treatment with AUY922 (FDR 
q­value = 0.003; Fig. 5 D).
HSP90 acts at the posttranscriptional level, thus imme­
diate targets (i.e., HSP90 clients) are not directly assessed by 
superior potency compared with the panel of JAK2 enzy­
matic inhibitors (Fig. 4, A and B). AUY922 was also highly 
active against a panel of Ba/F3 lines dependent on CRLF2 
and JAK2 (GI50, 1–11 nM; Fig. 4 B).
MHH­CALL4 and MUTZ­5 cells have constitutive 
phosphorylation  of  STAT5  (Y694),  JAK2  (Y1007/1008), 
JAK1 (Y1022/1023), ERK1/2 (T202/Y204), and AKT (S473; 
Fig. 4 C), which is indicative of activation of these pathways. 
Using RNAi to individually deplete the JAK family mem­
bers, we confirmed that STAT5 phosphorylation in MHH­
CALL4 cells is dependent on JAK2 (Fig. 4 D). Treatment 
with  JAKinh­1  for  16  h  reduced,  but  did  not  eliminate 
pSTAT5 and pERK1/2 in both lines. JAKinh­1 had little 
effect on pJAK1 and promoted increases in pAKT in MUTZ­5 
and pJAK2 in MHH­CALL4 (Fig. 4 C), as observed in 
Ba/F3­JAK2 V617F cells treated with BVB808 (Fig. 3 B).
Treatment  with  AUY922  for  16  h  more  extensively   
reduced  or  eliminated  phosphorylation  of  all  the  targets.   
Total JAK2, and to a lesser extent JAK1, were also reduced 
in  AUY922­treated  cells  (Fig.  4  C).  AUY922  promoted 
HSP70 up­regulation in both lines (Fig. 4 B), a known heat 
shock factor 1 (HSF1)–mediated pharmacodynamic response 
to  HSP90  inhibition.  Similar  effects  on  pJAK2,  pStat5, 
pErk1/2, and pAkt were observed in Ba/F3­CRLF2/JAK2 
R683S cells treated with the HSP90 inhibitors HSP990 (GI50, 
14.9 nM; unpublished data) or PU­H71 (GI50, 85.7 nM;   
Cerchietti et al., 2009; Fig. 4 E). Only MHH­CALL4 has 
constitutive phosphorylation of STAT1, and this was elimi­
nated by treatment with either JAKinh­1 or AUY922.
The  combination  of  AUY922+JAKinh­1  had  little  or   
no additional effect on target phosphorylation compared   
Figure 5.  Transcriptional profiling of JAK2 and HSP90 inhibition in CRLF2-rearranged B-ALL cell lines. MHH-CALL4 and MUTZ-5 cells were treated in 
triplicate for 14 h with either 1 µM JAKinh-1, 50 nM AUY922, the combination of both (combo), or vehicle. (A) Unsupervised hierarchical clustering of transcriptional 
profiles. (B) Hierarchical clustering and heat map of the most differentially expressed genes within the top/bottom 20 (FDR < 0.25 and FC > 2.5) between a treatment 
group and vehicle for MUTZ-5 and MHH-CALL4 cells. More abundant genes are visualized on the colorimetric scale in red, less abundant genes in blue. (C) GSEA was 
performed for each treatment condition with STAT5A and HSF1 gene signatures. (D) A JAK inhibitor signature was determined from the top/bottom 250 most differ-
entially expressed genes after treatment with JAKinh-1. This signature was used to perform GSEA for comparison AUY922 versus vehicle treatment.JEM Vol. 209, No. 2 
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HSP90 inhibition is effective against human  
CRLF2-rearranged B-ALL in vivo
To extend our findings to the in vivo treatment of human   
B­ALL, we established primary B­ALL xenografts from 
CRLF2­rearranged,  patient­derived  bone  marrow  samples   
(n = 40 for each sample) in NOD.Cg­Prkdcscid Il2rgtm1Wjl/SzJ 
(NSG)  mice.  Patient  sample  412  harbors  a  CRLF2/IGH 
translocation and a JAK2 R683S mutation. Patient sample 
537 harbors a P2RY8-CRLF2 rearrangement and lacks a 
somatic mutation within the known components of CRLF2 
signaling, based on transcriptome and exome sequencing 
(unpublished  data).  To  stringently 
assay established disease in vivo, we 
sacrificed sentinel animals weekly after 
transplantation to assess engraftment. 
Once bone marrow leukemia burden 
exceeded 30% (based on flow cytom­
etry of sentinel mice for human CD45), 
we initiated treatment with 50 mg/kg 
BVB808 twice daily by oral gavage, 
50  mg/kg  AUY922  thrice  weekly 
i.v., BVB808+AUY922, or vehicle. 
The  dose  of  BVB808  was  selected 
based on the demonstrated activity at 
this dose in Jak2 V617F–driven MPNs 
(Fig. 1, H–J) and previous studies that 
demonstrated  weight  loss  at  higher 
doses (not depicted).
After 5 d of treatment, we sacrificed 
animals to assess pharmacodynamic   
transcriptional profiling. We used the C3 database from the 
MsigDB  compendium  to  perform  a  transcription  factor–
binding  site  enrichment  analysis  of  the  most  differentially   
expressed genes between JAKinh­1 and AUY922. The top 
five ranked transcription factor–binding sites enriched in the 
AUY922­treated  group  were  all  heat­shock  factors  (HSF; 
FDR < 0.05), which are known to be transcriptionally re­
sponsive to HSP90 inhibition (Neckers, 2007). GSEA re­
vealed  that  an  HSF1  signature  was  only  enriched  upon 
treatment with AUY922 or AUY922+JAKinh­1, but not 
with JAKinh­1 alone (Fig. 5 C).
Figure 6.  JAK2 and HSP90 inhibition in 
CRLF2-rearranged human xenografts. NSG 
mice were injected with primary 412 or 537 
cells i.v. (n = 40 per line). When leukemia 
engraftment was >30% in the bone marrow, 
mice were divided into 4 treatment groups: 
50 mg/kg AUY922 i.v. thrice weekly, 50 mg/kg 
BVB808 by oral gavage twice daily, combina-
tion, or vehicle. (A) Immunohistochemistry 
using H&E or antibodies against human CD45 
(hCD45), pSTAT5, or HSP70 in spleens  
obtained from NSG mice engrafted with 412 
leukemias. Mice were treated for 5 d, and 
spleens were harvested 2–4 h after the  
last dose. (B) Immunoblotting of lysates  
from spleens obtained from NSG mice  
engrafted with 412 or 537 leukemias and 
then treated for 5 d with the indicated 
agent(s). (C) Unsupervised hierarchical clus-
tering of transcriptional profiles of 412 or 537 
leukemias engrafted in NSG mice after treat-
ment with BVB808, AUY922, BVB808+AUY922 
(combination), or vehicle. (D) Survival among 
NSG mice engrafted with primary human 
CRLF2-rearranged B-ALL samples and treated 
with BVB808, AUY922, combination, or  
vehicle. *, P < 0.05 compared with vehicle;  
**, P < 0.05 compared with BVB808.268 HSP90 inhibition targets resistant JAK2 | Weigert et al.
An alternative possibility is that genetic resistance to JAK 
enzymatic inhibitors is confined to only a few residues, as 
other mutations either confer only a small magnitude of re­
sistance or compromise JAK2 function. Other groups have 
reported additional mutations that confer resistance (Table S2), 
although many of these mutations are outside the ATP­binding 
pocket or P­loop, raising questions about their effects. It will 
be important to stringently assay the dependence of cells 
expressing these alleles on JAK2 enzymatic activity, as we did 
for E864K, Y931C, and G935R. Notably, mutations in the 
kinase domain of BCR/ABL1 have altered kinase activity 
and  transformation  potency  (Griswold  et  al.,  2006).  Both 
G935R and E864K promoted a competitive growth disad­
vantage in Ba/F3 cells. This disadvantage was reversed by 
treatment with BVB808 but suggests that, akin to clones har­
boring imatinib­resistance mutations, clones harboring either 
of these mutations would be outcompeted in vivo by clones 
lacking  a  resistance  mutation  in  patients  who  discontinue 
JAK inhibitor treatment.
The HSP90 ATPase is a molecular chaperone central to 
the conformational maturation of numerous client proteins, 
including a multitude of oncogenic factors involved in cancer 
cell growth and survival (Richardson et al., 2011). Recently, 
JAK2 has been shown to be an HSP90 client (Marubayashi   
et al., 2010), and HSP90 inhibitors are active in preclinical 
models of MPN in vitro and in vivo. We demonstrated that 
HSP90 inhibition overcomes genetic resistance within JAK2 
to enzymatic inhibitors. In fact, we observed a lower GI50 
value for AUY922 in VF cells harboring any of the three 
resistance mutations compared with cells lacking a resistance 
mutation (Fig. 2, G and H; and Table S1), suggesting an 
increased requirement for HSP90 activity.
We also noted persistent JAK2 signaling upon treatment 
of B­ALL cells harboring CRLF2 rearrangements and JAK2 
mutations with enzymatic JAK2 inhibitors. Similar increases 
in pJAK2 upon treatment of JAK2­dependent cells with   
enzymatic JAK inhibitors have been reported (Grandage   
et al., 2006; Haan et al., 2009; Hart et al., 2011). For MUTZ­5 
and MHH­CALL4 cells, GI50 concentrations with multiple 
JAK inhibitors were 20–40­fold higher than those observed for   
Jak2 V617F­dependent myeloid cell lines. In contrast, CRLF2­
rearranged B­ALL cell lines were highly sensitive to structurally 
divergent HSP90 inhibitors. HSP90 inhibition was associated 
with more potent disruption of JAK2 signaling in CRLF2­
rearranged B­ALL cells, as indicated by both posttranslational 
and transcriptional endpoints. It will be important to validate 
the transcriptional findings in additional datasets.
The greater suppression of JAK2 signaling upon treat­
ment with HSP90 inhibitors correlated with prolonged sur­
vival  of  mice  bearing  primary  human  B­ALL  xenografts. 
Thus, AUY922 had superior activity compared with the 
panel of JAK2 enzymatic inhibitors in CRLF2­rearranged   
B­ALL in vitro and compared with BVB808 in vivo. It remains 
possible that an alternative JAK2 inhibitor would have more 
activity against JAK2­dependent B­ALL in vivo. However, the 
high GI50 values noted upon treatment of MHH­CALL4 
endpoints. Spleens from mice treated with vehicle or BVB808 
had nearly complete effacement by B­ALL, whereas AUY922 
or BVB808+AUY922 treatment resulted in visible islands of 
hematopoiesis (Figs. 6 A). Based on immunohistochemistry, 
mice receiving AUY922 or BVB808+AUY922 (combo), but 
not BVB808 or vehicle, had nearly complete loss of pSTAT5 
and up­regulation of HSP70 (Fig. 6 A). Immunoblotting 
of spleens from treated mice demonstrated similar findings   
to those observed after treatment of MUTZ5 and MHH­
CALL4  (Fig.  4  B);  specifically,  reductions  in  pSTAT5, 
pJAK2, and total JAK2 in AUY922­ or BVB808+AUY922­
treated mice (Fig. 6 B). In contrast, treatment with single­
agent BVB808 only modestly suppressed pSTAT5 (Fig. 6 B). 
As  noted  in  MHH­CALL4  cells,  treatment  with  either 
BVB808 or AUY922 reduced pSTAT1 (Fig. 6 B).
We performed transcriptional profiling on bone marrow 
from mice after 5 d of treatment. Unsupervised hierarchical 
clustering (Fig. 6 C) demonstrated the same pattern of clus­
tering observed after treatment of B­ALL cell lines (Fig. 5 A). 
Specifically, mice treated with AUY922 or BVB808+AUY922 
clustered  together,  whereas  vehicle­  and  BVB808­treated 
mice clustered together (Fig. 6 C), indicating the dominant 
impact of HSP90 inhibition.
Treatment with either BVB808 or AUY922 prolonged 
overall survival compared with vehicle (Fig. 6 D; P = 0.01 
for both xenografts). Treatment with AUY922 further pro­
longed overall survival compared with BVB808 (P < 0.01 for 
both xenografts), whereas the combination of BVB808 and 
AUY922 had no additional benefit compared with AUY922 
alone (Fig. 6 D).
DISCUSSION
In this study, we describe point mutations near the ATP­
binding region of the JAK2 kinase (JH1) domain that confer 
resistance to a broad panel of enzymatic JAK inhibitors. All 
three mutations are in regions homologous to imatinib resis­
tance hotspots in ABL1 (Azam et al., 2003; Soverini et al., 
2011) and promote multiagent resistance in the context   
of Jak2 V617F or JAK2 R683G.
Our screen recovered only three amino acid substitutions 
capable of supporting growth in the presence of BVB808 
while maintaining JAK2 R683G function. In contrast, the 
previous  mutagenesis  screens  with  BCR/ABL1  recovered 
112 distinct amino acid substitutions affecting 90 residues 
(Azam et al., 2003). It is possible that we only recovered a 
small fraction of the mutations capable of conferring resis­
tance to JAK inhibitors. If so, recovery might have been lim­
ited by screening with 1 µM BVB808, which exceeded the 
GI50 of the parental cell line (28 nM) by >30­fold. However, 
selection in lower doses resulted in escape clones that lacked 
JAK2 mutations (unpublished data). Selection in a relatively 
high dose of BVB808 may also explain why we did not iden­
tify mutations outside the kinase domain. These mutations 
were reported in imatinib­resistant BCR/ABL1, but are typ­
ically associated with only a modest increase in GI50 (Azam   
et al., 2003).JEM Vol. 209, No. 2 
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multicloning site of pMSCVpuro (Takara Bio Inc.) using the Gateway Vector 
Conversion System (Invitrogen), as previously described (Yoda et al., 2010).
In separate aliquots, we mutagenized a total of 100 ng DNA by 
transformation  and  propagation  in  XL­1  Red  competent  Escherichia  coli 
(Stratagene),  according  to  the  manufacturer’s  recommendations.  Plasmid 
DNA was isolated using Nucleobond Xtra Midi kit (Takara Bio Inc.). For 
retrovirus production, we co­transfected the mutagenized JAK2 R683G 
cDNA library and the retroviral packaging construct pEcoPack (Takara Bio 
Inc.) at a 1:1 ratio into 293T cells using Lipofectamine 2000 (Invitrogen). 
After 48 h, we harvested the supernatant, passed it through a 0.45­µm filter 
(Millex; Millipore), and transduced 30 × 106 IL­3–dependent Ba/F3 cells 
that stably express CRLF2puro/IL7R­GFP. After 1 d, we washed the cells 
and  resuspended  them  in  fresh  IL­3–containing  media  substituted  with   
puromycin 1 µg/ml (Sigma­Aldrich). After another day, we changed media 
to no IL­3 and added 1 mg/ml neomycin (G418; Gold Biotechnology). 
Cells were then plated onto 96­ or 384­well plates in the presence or   
absence of 1 µM BVB808. Clones that survived BVB808 treatment were   
expanded in fresh RPMI 1640 media in the presence of puromycin/ 
neomycin/BVB808 and the absence of IL­3. We isolated genomic DNA 
using  QIAamp  DNA  Blood  Mini  kit  (QIAGEN)  and  amplified  cDNA   
in pMSCVpuroatt using the following primers: forward primer 5­TCCTC­
CCTTTATCCAGCCCTCACTCCTTCTCTAGG­3,  reverse  primer 
5­CTAAAGCGCATGCTCCAGACTGCCTTGGGAAAAGC­3.
PCR products were recloned into retroviral expression vector using 
Gateway BP/LR Cloning System (Invitrogen), and the ability to confer 
BVB808  resistance  was  confirmed  by  transduction  and  selection  in 
CRLF2puro/IL7R­GFP–expressing  Ba/F3.  cDNA  inserts  from  resistant 
clones were then PCR amplified and Sanger sequenced (full length) at the 
Dana Farber Cancer Institute Molecular Biology Core Facilities or the 
DF/HCC DNA Sequencing Facility. Site­directed mutagenesis was per­
formed using the QuikChange II XL site­directed mutagenesis kit (Strata­
gene). Each mutant allele was confirmed by sequencing, introduced into 
HA-hJAK2 pMSCVneoatt constructs, and then transduced into the appro­
priate Ba/F3 background. Stably transduced cells were tested for expression 
of JAK2 by immunoblotting for hemagglutinin (mouse anti­HA; Covance).
siRNA knockdown. IL­3–independent Ba/F3­EpoR cells expressing Jak2 
V617F (MSCV­IRES­GFP) with or without E864K, Y931C, or G935R 
were  transfected  with  either  nontargeting  control  siRNA  (siGENOME 
Non­Targeting siRNA #3) or siRNA against mouse Jak2 (siGENOME 
siRNA JAK2) by nucleofection (Cell Line Nucleofector kit V; Lonza) 
according to the manufacturer’s recommendation (X­001 program opti­
mized for Ba/F3 cells). Per reaction 1–2 × 106 cells were resuspended   
in Nucleofector Solution V in the presence of 150–300 nM siRNA. For 
Western blot analysis, two reactions were pooled and a third reaction was used 
for functional assays (CellTiter­Glo Luminescent Cell Viability Assay; Pro­
mega). Ba/F3 cells expressing an oncogenic ALK rearrangement (ATIC­ALK) 
were used as a control for JAK2­independent growth in non­IL­3–containing 
media. Results from this siRNA knockdown experiment were confirmed in 
three independent experiments.
Immunoblotting. Cells grown at 0.5 × 106/ml were harvested after in­
dicated treatment, washed in PBS, and collected in RIPA lysis buffer 
(Sigma­Aldrich) containing Protease Inhibitor (Sigma­Aldrich). Protein 
concentrations were determined by the BCA method (Thermo Fisher 
Scientific) and equal amounts were loaded onto precast 4–12% NuPAGE 
gels (Invitrogen). Western blotting was performed with appropriate dilu­
tions of primary and secondary antibody. Antibodies were directed against 
tubulin (T9026; Sigma­Aldrich), HA (MMS­101P; Covance), HSP70 (4876S; 
Cell Signaling Technology), CRLF2 (R&D Systems), STAT5 (SC­835; 
Santa Cruz Biotechnology, Inc.), phospho­STAT5 (4322; Cell Signaling 
Technology), JAK2 (32305; Cell Signaling Technology), phospho­JAK2 
(3776S; Cell Signaling Technology), AKT (4691S; Cell Signaling Technology), 
phospho­AKT (4060S; Cell Signaling Technology), ERK1/2 (4695B; Cell   
Signaling Technology), phospho­ERK1/2 (4370S; Cell Signaling Technology),   
and MUTZ­5 with any of the JAK enzymatic inhibitors 
(Fig. 4 B) argues against this possibility.
The lack of synergy between JAK and HSP90 inhibitors 
combined with the enrichment of a JAK inhibitor signature 
upon  treatment  of  MHH­CALL4  and  MUTZ­5  with 
AUY922 (Fig. 5) suggests that AUY922 is primarily func­
tioning through inhibition of JAK2 signaling. However, the 
HSP90 chaperone complex stabilizes a large number of client 
proteins, including multiple factors involved in signaling cas­
cades that affect proliferation and survival (Neckers, 2007; 
Trepel et al., 2010). Not surprisingly, HSP90 inhibitors like 
AUY922 (Eccles et al., 2008) have broad activity against a 
variety of hematologic and epithelial cell lines. This raises the 
possibility that the cytotoxic effects of HSP90 inhibitors in 
JAK2­dependent cells involve additional pathways beyond 
JAK–STAT signaling. A prime candidate is AKT, which is 
known to be an HSP90 client and can be therapeutically 
targeted in a large fraction of B­ALL cases (Abramson et al., 
2009;  Levy  et  al.,  2009;  Sanda  et  al.,  2010).  However, 
AUY922 had minimal effects on total AKT in MUTZ­5 and 
MHH­CALL4 cells (Fig. 4). In addition, AUY922 at con­
centrations between 25–400 nM can reversibly inhibit the   
in vitro proliferation of bone marrow stromal cells (Stühmer   
et al., 2008), raising the possibility that some AUY922 effect 
could be leukemia cell–extrinsic.
In conclusion, we demonstrate that resistance to a panel 
of JAK enzymatic inhibitors, through either kinase domain 
mutation or incomplete inhibition of JAK2 signaling, can be 
overcome by inhibition of HSP90. These studies provide a 
proof­of­concept for the therapeutic targeting of HSP90 in 
JAK2­dependent cancers and establish the rationale for clinical 
evaluation of this concept.
MATERIALS AND METHODS
Reagents and cell lines. Jak Inhibitor I, a pan Jak inhibitor, was purchased 
from EMD. NVP­BSK805, BVB808, and AUY922 were provided by 
Novartis. TG101348 was synthesized by the Memorial Sloan­Kettering 
Cancer Center Organic Synthesis Core Facility. Tofacitinib was pur­
chased  from  Selleck.  17­AAG  was  purchased  from  Selleck.  PU­H71   
6­amino­8­[(6­iodo­1,3­benzodioxol­5­yl)thio]­N­(1­methylethyl)­9H­purine­ 
9­propanamine hydrate was synthesized by the Chiosis Laboratory. Stock 
aliquots were prepared in DMSO, stored at –20°C, and diluted in appro­
priate media before use.
Ba/F3 (American Type Culture Collection) cells were maintained in 
RPMI 1640 medium (Invitrogen) with 10% FCS (Invitrogen) and 500 pg/ml 
IL­3 (Millipore) or 1 ng/ml TSLP (R&D Systems). Ba/F3 were stably trans­
duced with CRLF2 (MSCVpuro), IL7R (MSCV­GFP), EpoR (MSCVpuro), 
HA-JAK2 (MSCVneo), and Jak2 (MSCV­IRES­GFP) with or without activat­
ing mutations in the pseudokinase domain (R683G or V617F) as indicated.
The  B­ALL  cell  lines  MUTZ­5  (harbors  IGH/CRLF2  and  JAK2 
R683G) and MHH­CALL4 (harbors IGH/CRLF2 and JAK2 I682F) cells 
were obtained from Deutsche Sammlung von Mikroorganismen und Zellkul­
turen (Braunschweig, Germany) and grown in RPMI 1640 with 20% FBS.
Random mutagenesis screen of human JAK2 R683G. We modified a 
previously described approach (Azam et al., 2003) to generate a randomly 
mutagenized cDNA library of human JAK2 R683G. In brief, JAK2 R683G 
was cloned into the retroviral expression vector pMSCVneoatt, which was 
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Mice were injected with primary 412 or 537 cells i.v. via the lateral tail vein 
without prior irradiation. Full hematologic analysis was performed on   
1 mouse from each group every 2 wk, with the presence of human leukemia 
cells detected using a human­specific anti­CD45 antibody. When leukemia 
was established with bone marrow blasts >30%, mice were divided into   
4 treatment groups: AUY922 (50mg/kg i.v. thrice weekly), BVB808 (50 mg/kg   
by gastric lavage twice daily), combination, and vehicle. The BVB808 regi­
men was based on efficacy against JAK2 V617F­driven myeloproliferation 
(Fig. 1, H–J). The AUY922 regimen was based on preclinical studies in a 
breast cancer xenograft model (Jensen et al., 2008). 3 wk after starting treat­
ment with AUY922 alone or in combination, AUY922 administration was 
switched to intraperitoneal because of scarring of the lateral tail vein with the 
same dose and schedule. Mice were sacrificed when they developed hind 
limb paralysis or became moribund.
To assess the pharmacodynamic efficacy of treatments, a separate cohort   
of mice were analyzed after 5 d of treatment. 2–4 h after the last dose, mice were 
euthanized and tissues fixed by perfusion with 10% formalin. Spleen, femur, and 
liver were collected and further fixed in 10% neutral­buffered formalin for   
immunohistochemistry, Western blotting, and isolation of nucleic acids.
These animal studies were performed under Dana Farber Cancer Center 
Animal Care and Use Committee approved protocols.
X-ray micro-CT imaging. Using the micro­CT on a multimodality pre­
clinical imaging system (Inveon: Siemens Healthcare), longitudinal x­ray 
computed tomography (CT) scans were performed for a subgroup of mice 
(n = 7) used in this study, to follow their spleen sizes in vivo (and excluded 
from other analyses). For improving spleen visualization and quantification 
accuracy, each mouse was injected (i.v. 70 µl) with a nanoparticle CT 
contrast agent (Viscover ExiTron nano 12000; Miltenyi Biotec) a few hours 
before the first (baseline) CT scan. Subsequent scans (3 d, 1 wk, 2 wk, and 
7 wk after baseline) required no reinjections. At each time point, the mice 
were first anesthetized by inhalation of a mixture of sevoflurane and medical 
air, and then underwent a previously established CT imaging protocol (80 kVp, 
0.5 mA, 220 degree rotation, 1 s/degree exposure, 80 µm reconstruction 
pixel size).
The reconstructed volumetric CT data were visualized and analyzed   
using Amira (version 5.3.3; Visage Imaging). Because ExiTron nano accu­
mulates in liver and spleen, resulting in good image contrasts between these 
organs and adjacent soft tissues, a threshold­based semiautomatic method 
available in Amira was used for spleen segmentation. In the occasional events 
where the boundaries between the liver and spleen were not properly 
detected, manual delineations were also used. All segmentations were visu­
ally confirmed for anatomical consistencies through three­dimensional 
volume renderings, after which the spleen volumes were automatically cal­
culated by the software. Immediately after the last imaging time point, the 
spleen in each mouse was exercised and weighed. A simple linear regression 
analysis was performed between the spleen volumes measured by CT and 
the weights measured.
Gene expression profiling, differential analysis, and GSEA. MUTZ­5 
and MHH­CALL 4 cells grown at a concentration of 106 cells/ml were 
treated with vehicle (DMSO), JAKinh­1 (1 µM), AUY922 (50 nM), or the 
combination of both for 14 h, each in triplicate. Total RNA was isolated   
using TRIzol reagent (Invitrogen). RNA was also isolated from mouse bone 
marrow infiltrated by human CRLF2­rearranged leukemia primary xeno­
grafts 412 and 537 after 5 d of treatment with BVB808, AUY922, the com­
bination, or vehicle, as outlined above. Hematoxylin and eosin staining and 
immunohistochemistry  with  anti­hCD45  antibody  demonstrated  >80%   
tumor cell infiltration in all samples.
RNA was hybridized to Affymetrix U133_Plus2 chips at the Dana 
Farber Cancer Center Microarray Core. All analyses were performed using 
Gene Pattern (Broad Institute, http://www.broadinstitute.org/cancer/
software/genepattern; Reich et al., 2006). Raw probe­level data from 
Affymetrix .CEL files were summarized using the Robust Multiarray Average 
(RMA)  procedure  available  through  the  ExpressionFileCreator  module   
in Gene Pattern. Using the preprocessing module, a variation filter was 
STAT1 (SC­346; Santa Cruz Biotechnology, Inc.), and phospho­STAT1 
(9167S; Cell Signaling Technology).
In vitro inhibitor assay. Viable cells were plated in white opaque 384­well 
plates (50 µl/well; Corning) using EL406 Combination Washer Dispenser 
(BioTek) at a density of 0.01–0.05 × 106 cells/ml (Ba/F3) and 0.25 × 106 cells/ml 
(MUTZ­5 and MHH­CALL4). Inhibitors or vehicle (DMSO) were added   
using a JANUS Automated Workstation (PerkinElmer). After 48 h (Ba/F3 
cells) or 96 h (Mutz­5 and MHH­CALL4), CellTiter­Glo Luminescent 
Cell Viability Assay was added (25 µl each well) and read by the 2104   
EnVision Multilabel Reader (PerkinElmer). Each data point was quantified   
in quadruplicate and experiments were repeated at least twice. Analysis of 
pairwise dose–response data and isobologram plots was done according to the 
median­effect principle of Chou and Talalay (1984; CalcuSyn Software). Dose–
response curves and plots were generated with GraphPad Prism software.
Measurement of inhibition of JAK in vitro kinase activity and assess­
ment of antiproliferative activity, as well as biochemical profiling in SET­2, 
MB­02, UKE­1, MV4;11, CMK and K­562 cell lines was performed as 
previously described (Baffert et al., 2010)
Competitive growth assay. Ba/F3­EpoRpuro cells were stably transduced 
with Jak2 V617F (MSCV­Thy1.1) or Jak2 V617F plus one of the three 
kinase domain mutations (MSCV­IRES­GFP). Cells were mixed at a 1:1 ratio 
and cultured in media lacking IL­3. In addition, cells were treated with either 
1 µM BVB808 or 10 nM AUY922. Cells were stained with PE­anti­Thy1.1 
(mouse anti–rat CD90.1, clone OX­7; BD) and flow cytometry was per­
formed daily for 3 d and thereafter as indicated. The viable population was 
estimated based on forward scatter and side scatter.
In vivo murine experiments. Mouse bone marrow transplants were per­
formed essentially as previously described (James et al., 2005). In brief, 
female BALB/c mice 8–9 wk of age were lethally irradiated (2 doses of 4.5 Gy 
with 4­h interval using the BIOBEAM 8,000  irradiator), and then trans­
planted with 3 × 106 donor bone marrow cells (injected i.v. into the tail vein 
in a total volume of 200 µl HPBS, pH 7.4) that had been transduced with 
pMSCV Jak2 V617F­IRES­GFP retrovirus. Complete blood counts (CBC) 
were typically determined 4–6 wk after transplant using a blood analyzer 
(Sysmex XT­2000i), and mice were randomized into treatment groups 
based on hematocrit. Dosing with vehicle or 50 mg/kg BVB808 by oral   
gavage twice daily was initiated the following day.
After 3 wk of dosing, animals were given a final dose and sacrificed 2 or 
12 h later for analyses. Sterna and femurs were removed en bloc, fixed for 48 h 
in 10% neutral­buffered formalin at room temperature, and then washed   
in PBS and decalcified in EDTA­citric acid buffer, pH 7.5, (Biocyc GmbH) 
for 3 × 24 h at 37°C. After a last wash in PBS, the tissues were cut up and 
placed with the surface of interest facing downward into a universal histocas­
sette, followed by processing in a TPC 15Duo (Tissue Processing Center) 
for paraffinization. Spleen samples were processed for histology and pStat5 
immunohistochemistry as previously described (Baffert et al., 2010). Animals 
were kept under OHC conditions with free access to food and water. These 
experiments were performed in strict adherence to the Swiss Law for Animal 
Welfare and approved by the Swiss Cantonal Veterinary Office of Basel­Stadt.
Transplantation of luciferized Ba/F3 cells into nude mice and monitor­
ing of luciferase activity was performed as previously described (Weisberg   
et al., 2007). In brief, male NCr­nude mice (5–6 wk of age; Taconic) were 
given a mixture of 1,000,000 VF­Thy1.1­luc+ cells and 1,000,000 VF­GFP­luc+ 
cells by tail vein injection. Baseline imaging was performed to establish 
bioluminescence (day 4), and then mice were randomly divided into treat­
ment cohorts (vehicle vs. AUY922). Imaging was done at indicated intervals 
until day 8, when the first death occurred. Mice were followed for survival 
and sacrificed when they developed hind limb paralysis or became moribund.
Two primary human B ­ALLs were xenotransplanted into a total of 80 
6­wk­old NSG mice. Sample 412 harbors a CRLF2/IgH translocation and 
a JAK2 R683S mutation. Sample 537 harbors a P2RY8-CRLF2 rearrangement 
and lacks a somatic mutation within the known components of CRLF2 
signaling, including IL7R, CRLF2, TSLP, JAK1, JAK2, and STAT5A/B. JEM Vol. 209, No. 2 
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applied (threefold minimum change and 100 minimum absolute difference) 
and values were thresholded at 10, leaving 11,751 probes representing 6,720 
genes  in  the  dataset.  After  log2  transformation  a  differential  analysis   
of markers in the union of cell lines between different treatment conditions 
(union of all cell lines treated with the same drug) and vehicle was performed 
using the comparative marker selection module. For visualization up to 
20 most differentially expressed probes were selected based on an FDR q­value 
<0.25 and a fold change >2.5. Visualization and hierarchical clustering of 
probes using Pearson correlation was done with GEN­E software (Broad   
Institute; http://www.broadinstitute.org/cancer/software/GENE­E/dev/).
The JAK inhibitor signature was defined to encompass the top and 
bottom 250 most differentially expressed genes between vehicle (DMSO) 
and JAKinh­1. The JAK inhibitor signature was subsequently tested for   
enrichment in the DMSO versus AUY922 group using the GSEA method 
as previously described (http://www.broadinstitute.org/gsea/index.jsp; 
Subramanian et al., 2005). To capture common transcription factor binding 
motifs within the most differentially expressed genes between the DMSO 
and AUY922 treatment arm GSEA was performed with the publically 
available C3­transcription factor site database from the MsigDB repository 
(Broad  Institute,  http://www.broadinstitute.org/gsea/msigdb/index.jsp5, 
(Subramanian et al., 2005). Subsequently, GSEA was performed for each 
treatment  condition  using  the  predefined  gene  sets  for  either  STAT5A 
(V$STAT5A_01,  V$STAT5A_02,  V$STAT5A_03,  V$STAT5A_04)  and 
HSF1 (RGAANNTTC_V$HSF1_01), from the publically available path­
way repository MSigDB (Broad Institute; http://www.broadinstitute.org/
gsea/msigdb/index.jsp5).
Online supplemental material. Supplementary information for this study 
includes information on IC50 concentrations for JAK enzymatic inhibitors 
and HSP90 inhibitors in Ba/F3 cell lines (Table S1), previous studies describ­
ing JAK2 mutations that confer resistance to enzymatic inhibitors (Table S2), 
most differentially regulated genes in MHH­CALL4 and MUTZ­5 cells 
upon treatment with inhibitors (Table S3), and BVB808 pharmacokinetics   
(Fig. S1). Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20111694/DC1.
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